Cover Image
市場調查報告書

全球皮膚疾病治療藥市場預測

Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

出版商 GBI Research 商品編碼 358647
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
全球皮膚疾病治療藥市場預測 Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth
出版日期: 2016年05月01日 內容資訊: 英文 144 Pages
簡介

全球皮膚疾病治療藥市場,預計從2015年的200億美元,擴大到2022年的337億美元,預計2015年∼2022年以7.73%的年複合成長率成長。

本報告提供皮膚疾病治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 上市產品

  • 概要
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Enbrel (etanercept)
  • Stelara (ustekinumab)
  • Neoral (cyclosporine)
  • Protopic (tacrolimus)
  • Elidel (pimecrolimus)
  • Elocon (mometasone furoate)
  • Differin (adapalene)
  • Metolate (methotrexate)
  • Clobex (clobetasol propionate)
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台的分子類型
  • 開發平台的分子標的
  • 臨床實驗情形
  • 結論

第5章 複數方案的市場預測

  • 市場規模全體
  • 學名藥的普及
  • 收益預測:各分子標的

第6章 企業分析與地位

  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC390MR

Executive Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Scope

The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.

Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?

Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.

  • Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
  • What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
  • Visualize the composition of the dermatology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various dermatological conditions.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Atopic Dermatitis
    • 2.3.2. Acne Vulgaris
    • 2.3.3. Psoriasis
  • 2.4. Co-morbidities and Complications
  • 2.5. Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
    • 2.5.1. Atopic Dermatitis
    • 2.5.2. Acne Vulgaris
    • 2.5.3. Psoriasis
  • 2.6. Treatment
    • 2.6.1. Topical Corticosteroids
    • 2.6.2. Calcineurin Inhibitors
    • 2.6.3. Retinoids
    • 2.6.4. Systemic Immunosuppressive Agents
    • 2.6.5. Biologics
    • 2.6.6. Antihistamines
    • 2.6.7. Hormonal Therapy
    • 2.6.8. Moisturizers

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Humira (adalimumab)
  • 3.3. Remicade (infliximab)
  • 3.4. Enbrel (etanercept)
  • 3.5. Stelara (ustekinumab)
  • 3.6. Neoral (cyclosporine)
  • 3.7. Protopic (tacrolimus)
  • 3.8. Elidel (pimecrolimus)
  • 3.9. Elocon (mometasone furoate)
  • 3.10. Differin (adapalene)
  • 3.11. Metolate (methotrexate)
  • 3.12. Clobex (clobetasol propionate)
  • 3.13. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Molecule Types in the Pipeline
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
  • 4.5. Conclusion

5. Multi-Scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Tumor Necrosis Factor-Alpha
    • 5.3.2. Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
    • 5.3.3. Calcineurin
    • 5.3.4. Glucocorticoid Receptors
    • 5.3.5. Phosphodiesterase 4
    • 5.3.6. Revenue and Market Share Analysis by Company
    • 5.3.7. Assessment of Key Pipeline Products

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of Epidemiology Forecast
  • 8.3. Table of All Clinical Stage Pipeline Products
  • 8.4. Abbreviations
  • 8.5. Disease List
  • 8.6. Methodology
    • 8.6.1. Coverage
    • 8.6.2. Secondary Research
    • 8.6.3. Market Size and Revenue Forecasts
    • 8.6.4. Pipeline Analysis
    • 8.6.5. Competitive Landscape
  • 8.7. Contact Us
  • 8.8. Disclaimer

List of Tables

  • Table 1: Dermatology, Global, Epidemiology of Dermatological Disorders, 2015
  • Table 2: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2015
  • Table 3: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2015
  • Table 4: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2015
  • Table 5: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2015
  • Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2015
  • Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2015
  • Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015
  • Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015
  • Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015
  • Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2015
  • Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2015
  • Table 13: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
  • Table 14: Dermatology, Global, Usage of Generics Across Key Indications, 2015
  • Table 15: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022
  • Table 16: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2016
  • Table 17: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2016
  • Table 18: Epidemiology Patterns for Atopic Dermatitis, 2015-2022
  • Table 19: Epidemiology Patterns for Acne Vulgaris, 2015-2022
  • Table 20: Epidemiology Patterns for Psoriasis, 2015-2022
  • Table 21: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016
  • Table 22: Abbreviations

List of Figures

  • Figure 1: Epidemiology Patterns for Atopic Dermatitis (Million), 2015-2022
  • Figure 2: Epidemiology Patterns for Acne Vulgaris (Million), 2015-2022
  • Figure 3: Epidemiology Patterns for Psoriasis (Million), 2015-2022
  • Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2015
  • Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2022
  • Figure 6: Dermatology Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006-2022
  • Figure 7: Dermatology Therapeutics Market, Global, Annual Revenue for Enbrel ($bn), 2006-2022
  • Figure 8: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2022
  • Figure 9: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2022
  • Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2022
  • Figure 11: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 12: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 13: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2016
  • Figure 14: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2016
  • Figure 15: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2016
  • Figure 16: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2016
  • Figure 17: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 18: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 19: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 20: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 21: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 22: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 23: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 24: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 25: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
  • Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 29: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
  • Figure 30: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 31: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 32: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 33: Dermatology Global, Market Size ($bn), 2015-2022
  • Figure 34: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
  • Figure 35: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015-2022
  • Figure 36: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
  • Figure 37: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022
  • Figure 38: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022
  • Figure 39: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2022
  • Figure 40: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 41: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 42: Dermatology, Global, Revenues by Product Type, 2015-2022
  • Figure 43: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
  • Figure 44: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2015-2022
  • Figure 45: Dermatology, Global, Amgen Annual Revenue Forecast ($bn), 2015-2022
  • Figure 46: Dermatology, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022
  • Figure 47: Dermatology, Global, Roche Annual Revenue Forecast ($bn), 2015-2022
  • Figure 48: Dermatology, Global, Merck Annual Revenue Forecast ($bn), 2015-2022
  • Figure 49: Dermatology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015-2022
  • Figure 50: Dermatology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2016-2022
  • Figure 51: Dermatology Therapeutics Market, Global, Revenue Forecast for dupilumab ($m), 2016-2022
  • Figure 52: Dermatology Therapeutics Market, Global, Revenue Forecast for AN-2728 ($m), 2016-2022
  • Figure 53: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022
  • Figure 54: Dermatology Therapeutics Market, Global, Revenue Forecast for guselkumab ($m), 2016-2022
  • Figure 55: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 56: Dermatology, Global, Companies by Type, 2016
  • Figure 57: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2016
  • Figure 58: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022
  • Figure 59: Dermatology, Global, Licensing Deals, 2006-2016
  • Figure 60: Dermatology, Global, Licensing Deals by Indication, 2006-2016
  • Figure 61: Dermatology, Global, Licensing Deals, 2006-2016
  • Figure 62: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
  • Figure 63: Dermatology, Global, Co-development Deals, 2006-2016
  • Figure 64: Dermatology, Global, Co-development Deals by Indication, 2006-2016
  • Figure 65: Dermatology, Global, Co-development Deals, 2006-2016
  • Figure 66: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016
Back to Top